Trial Profile
A French Post-market Observational/Non-interventional Study of the BioMatrix Flex and BioMatrix Neo Flex Drug Eluting Stents With 6-month DAPT
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Apr 2020
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary) ; Antiplatelets
- Indications Coronary artery restenosis
- Focus Adverse reactions
- Sponsors Biosensors Europe
- 14 Apr 2020 Status changed from active, no longer recruiting to completed.
- 14 Mar 2018 New trial record